This protocol addresses chronic hepatointestinal schistosomiasis caused by Schistosoma mansoni, in which ongoing intestinal and hepatic involvement leads to progressive organ damage. Infection is confirmed by the detection of eggs in faeces.
Management relies on a targeted oral antiparasitic agent delivered in a structured split-dose course. The complete regimen — including dosing schedule, inter-dose interval, and follow-up criteria — is detailed in the full protocol.
The primary endpoint is the absence of viable eggs in stool at three months after treatment; egg detection at that point indicates failure or reinfection. Resolution of eosinophilia is expected by six months and serves as a secondary marker of treatment success.
Hepatointestinal S.: abdominal pain, chronic diarrhoea, rectal bleeding, liver fibrosis, ascites, portal hypertension, splenomegaly, variceal bleeding
Egg detection in urine (S. h.) or faeces (other S. spp.)
S. h., S. man., S. i.: 60 mg/kg/d p.o. (in 2 or 3 doses) on day 0 and on day 21‑30
Detection of vital eggs 3 months after treatment indicates treatment failure or reinfection.
Eosinophilia should be cleared at 6 months after treatment
View source ↗